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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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A key Huntington’s disease trial remedy gets Orphan
Drug Designation, as yet another young life is cut
short
Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals) has achieved
another milestone in its search for a treatment for Huntington’s disease:
on January 5 the company announced that the U.S. Food and Drug
Administration (FDA) granted Orphan Drug Designation for its genesilencing drug, currently under study in a clinical trial in Europe and
Canada.
The FDA designation, intended to facilitate development of the test drug
IONIS-HTTRx by offering financial incentives and assistance, could not
come at a better time. Huntington’s disease patients – like 18-year-old
Terry Leach of San Diego, who died the morning of January 2 – continue
to succumb to this devastating, untreatable disorder.
“Although the toxic protein produced from the huntingtin (HTT) gene in
HD patients has been a target of interest for many years, IONIS-HTTRx is
the first therapy to enter clinical development that is designed to treat the
underlying cause of this fatal disease,” Frank Bennett, Ph.D., Ionis’s senior
vice president of research, said in a company press release. “The granting
of Orphan Drug Designation in both the U.S. and Europe highlights the
significant need for a drug that could transform the treatment of HD.”
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HD-affected Phase I clinical trial volunteers in London received the first
dosing of IONIS-HTTRx in the October 2015 (click here to read more).
IONIS-HTTRx could potentially reduce, partly reverse, and even prevent
symptoms.
Likely ending in 2017, Phase I is testing primarily for safety and
tolerability. If it is successful, Phase II and III trials measuring the drug
efficacy’s would ensue. Together the three phases of a trial typically take at
least five years. If the trial is successful, a drug could become available
around 2020.
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Frank Bennett, Ph.D. (photo by Dr. Ed Wild)
Increased dialogue, helpful benefits
“We were pretty excited to get Orphan Drug Designation,” Kristina
Bowyer, Ionis’s executive director of patient advocacy, said in a phone
interview on January 5. Ionis is based in Carlsbad, CA.
The designation means that the FDA recognizes “the severity of the disease
and the limited population,” she noted.
The designation creates an opportunity for increased dialogue between
Ionis and the FDA regarding the IONIS-HTTRx clinical trial, Bowyer
explained.
Such extra communication can help resolve the unique issues of orphan
disease trials. Because an orphan disease like HD involves fewer than
200,000 patients and very specific approaches to treatments, the design of
clinical trials is atypical, Bowyer said. The smaller number of potential
volunteers also means that the FDA might have to approve a smaller than
normal trial, and sometimes perhaps even a faster trial, she added.
“It’s an area where our technology is well-suited,” Bowyer continued,
referring to the antisense oligonucleotides that form the backbone of all
Ionis drugs. “We have been able to focus on several rare diseases with a
known target.”
By law, as outlined in the press release and in an e-mail from Bowyer, the
Orphan Drug Designation includes significant financial benefits for Ionis:
seven years of market exclusivity in the U.S. if the FDA approves the drug,
tax credits related to clinical trial expenses, FDA assistance in clinical trial
design, and a waiver of Prescription Drug User Fee Act filing fees – over $1
million per drug as of fiscal year 2009.
“These benefits help manufacturers recover the costs of developing a drug
for small numbers of people,” Bowyer wrote. The Orphan Drug Act was
signed into law in 1983.
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Kristina Bowyer (photo by Gene Veritas)
Trial ‘moving along well’
In IONIS-HTTRx, HTT stands for the gene huntingtin, and Rx for medical
treatment. The train has just recently begun, so, Ionis has reported no
official update at this time.
“Everything is moving along very well,” Bowyer said.
The new name
Ionis has also adapted well to its name change, announced on December
18, 2015, in response to concerns about confusing the name Isis
Pharmaceuticals, Inc., with the acronym “ISIS” used in the Englishlanguage media for the Middle Eastern terrorist organization, the Islamic
State. Isis Pharmaceuticals was founded in 1989.
“We want people when they hear or say our name to think about the
incredible drugs we’re developing and not a terrorist group,” Wade Walke,
Ph.D., vice president of communications and investor relations, told the
press.
Ionis chose its new name based on employee suggestions.
“It seemed to me that everybody came together and decided that Ionis was
a nice-sounding, feeling name, as soon as someone hit on it,” said Stanley
Crooke, M.D., Ph.D., Ionis’s chairman of the board and CEO. The new
moniker is a so-called empty vessel name and has no inherent meaning
other than what the company does, he added.
Said Dr. Crooke: “We’re here for the patients. We’re not here for our
name.”
(Disclosure: I hold a symbolic amount of Ionis shares.)
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The Ionis logo
Too late for Terry, other ‘HD angels’
I remember that Dr. Crooke spoke the same phrase – “We’re here for the
patients” – when I met him briefly during one of my first visits to the
company in the late 2000s.
I also remember visiting Terry Leach on Labor Day 2015. He was slowly
but inexorably slipping away from the ravages of juvenile HD, a
particularly devastating form of the disease (click here to read more about
my visit).
Nevertheless, I was still shocked by his death on January 2.
What a horrible time to lose a family member. New Year’s will forever
remind Terry’s mother Angela and his siblings of his passing.
My immediate reaction that morning was one of intense anger.
No 18-year-old should die!
Having had the privilege of knowing Terry and his family, I felt that I had
failed as an advocate to speed the progress towards treatments.
Why hadn’t the Ionis trial come in time to save Terry and the other
“Huntington’s disease angels” who have passed in recent weeks?
I know that HD researchers may have similar thoughts, as they work with
the specter of this killer disease ever looming.
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Terry Leach (family photo)
Keeping the faith
Later in the day, knowing that I needed to transcend my anger and
sadness, I recalled that a new year always brings hope. As I took a long,
strenuous walk with my dog through our hilly neighborhood, I renewed my
resolve to fight HD in 2016.
I spoke to Angela a few times that weekend. Instead of a wake and church
service, the family will hold a remembrance for Terry at the family home
on January 16. A Christian minister will preside.
At Angela’s request, I wrote some words for the back of the remembrance
cards she’s having made: “With his infectious smile and fortitude, Terry set
an example for all to follow. His life was short, but full of love and joy. He
is now free to walk with the Lord.”
Understandably, Angela was too drained to talk much. She did confirm
that Terry – despite his inability to talk, his confinement to a wheelchair,
and years of ingesting food through a feeding tube – had achieved his high
school diploma. He had attended school through mid-2015, receiving
assistance in a program for the disabled.
I asked Angela if she had any words for the HD community.
She said: “Just to keep their faith.”
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Angela Leach in 2012 holding artist Lee Ellingson's drawing of her son
Terry as "SuperTerry," the superhero who knocks out Huntington's
disease (photo by Gene Veritas)
Posted by Gene Veritas at 12:40 PM
Labels: clinical trials , drug , FDA , gene-silencing , huntingtin , Huntington's
disease , Ionis Pharmaceuticals , IONIS-HTT-Rx , Isis Pharmaceuticals , orphan
disease , Orphan Drug Desgination , symptoms , Terry Leach , treatments

2 comments:
Anonymous said...
Very interesting blog. Together with the family we look forward
to a new drug that will free us from this disease.
Greetings from Poland!
6:28 AM, January 09, 2016

Anonymous said...
Gene your contributions towards encouragement and research
in the HD field are great.
What horrifys me is the uneeded suffering of ones LIKE
Terry(don't know his history)! Excluding a limited number of
those born post the 90s where parents truly had no possible
knowledge of HD in their family or a late diagnosed ,
unplanned pregnancy there ought not be hardly any one born
positive or at risk for the HD gene.In 1993 the gene test for HD
had been found.
While an individual has a right to be too afraid too find out
curehd.blogspot.com/2016/01/a-key-huntingtons-disease-trial-remedy.html
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their at risk status, it's unethical with recent options to
procreate children with this HD gene risk. Just think if an at
risk person finds just sustaining awareness of the disease
affecting themselves how can such dare risking a child
becoming a victim of this disease?
What about promoting the reduction of this disease via
explaining the various levels of gene testing re embryos,preimplantation etc avoiding divulging parent's at risk status for
the extra afraid, suggesting no children or adoption or donor
sperm/eggs for super afraid and explaining the benefits of
finding out ones at risk status for the understandably anxious
though more open minded.
The other facts are that research has areas where pre
symtomatic at risk persons, the earlier the better can be
essesntial to furthering potential treatments. Furthermore, the
reality is that any treatments that may become relatively
effective will be so applied as early as possible as much of the
time more established damage is generally resistant to being
undone to any great extent.
HD will never have a true cure.Why?
Because no fetus, infant or unsymptomatic child who is at risk
may ever are identified to apply any most effective treatment as
the differences of HD gene positive persons means the
porential pathologies are already on their course.
Eventually some treatments will possibly arrive that may
provide some level of modifying the disease course in various
numbers for various persons and earlier stages.Still 10 - 15 yrs
away at best. Plus with the most treatable not daring to be
identified as at risk. More likely the best treatments for those
with an established level of HD might just slow down a bit
some parts of the disease in their progression. A small
difference, though a valuable gain for an individual, parallel to
a certain cancer treatments mesured by up to 5yrs extra life.
It's sad an irrational that testing for HD gene status is a taboo
topic,even for scientists to broach. Years go so fast that a
persons late 30's -40's is really quite brief when becoming
symtomatic will reveal one's avoided gene status.So avoidance
got one a spouse who in modern times can go as soon as your
symptomatic, got kids one with JDH, another who kills
themself on drugs afraid of having the disease as no reason was
ever applied to dealing with HD, no financial plans made re cut
earning times. In top of that alone and declining you can't
access any facilities and care that ought to and could have been
more there because the ones like you who had shame and fear
of being known to have HD in you or kin hid the true numbers
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of HD persons, an outdated legacy.
The fact HD can squeeze by as an orphan disease is shameful
but realistic through the hidden real number. Wheras the true
suspected number of at risk and persons who have even died of
HD either purposefully or via misdiagnosis available in figures
the actual number is assumed to be multiple times higher.This
is emerging though not used yet as data re HD incidence %
occurance in populations since in the last 20 yrs GPs and psych
services won't collude with avoiding a HD diagnosis re ethics
around promoting the option re information for potentially at
risk kin.
8:34 PM, February 26, 2016
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